Drug Development Cost Estimator

Model phase-by-phase drug development costs and see how NAMs integration can reduce your total program spend from preclinical through Phase III.

← Back to Tools

⚙️ Configure Your Estimates

% of preclinical using NAMs

Preclinical 31 mo
$31M
Discovery, lead optimization, IND-enabling
Animal Studies $12M
In Vitro / NAMs $4M
Other R&D $15M
↓ $3.2M with NAMs
Phase I 18 mo
$5.2M
Safety, tolerability, PK (20-80 subjects)
Clinical Operations $2.8M
Per-Subject Cost $60K
Phase II 30 mo
$18M
Efficacy, dose-finding (100-300 subjects)
Clinical Operations $10M
Per-Subject Cost $45K
Phase III 36 mo
$350M
Pivotal efficacy (1,000-5,000 subjects)
Clinical Operations $180M
Per-Subject Cost $50K
Total Program Cost 115 mo (~9.5 yrs)
$404M
Full development to NDA/BLA submission

📊 Traditional vs. NAMs-Enhanced Development

Traditional Approach
Preclin
I
II
III
$407M
NAMs-Enhanced (50%)
Preclin
I
II
III
$404M
Preclinical Savings
$3.2M
10% reduction in preclinical costs
Timeline Acceleration
4 mo
Faster preclinical completion
Risk-Adjusted Value
$8.5M
Including improved translation

📈 Success Rates by Therapeutic Area

Therapeutic Area Phase I → II Phase II → III Phase III → Approval Overall Success Avg. Cost to Market
Oncology 63% 33% 58% 5.3% $2.6B
Cardiovascular 70% 24% 62% 6.2% $1.9B
CNS / Neurology 65% 28% 50% 6.0% $2.1B
Metabolic 71% 43% 65% 12.0% $1.1B
Immunology 69% 38% 60% 9.5% $1.4B
Infectious Disease 75% 45% 68% 15.2% $0.9B
Rare Disease 72% 40% 66% 17.5% $0.8B

📋 Cost Assumptions

  • Costs are median industry values (2024 data)
  • Phase III varies significantly by indication
  • Does not include cost of failures
  • Excludes regulatory filing fees ($3-5M)
  • Manufacturing scale-up not included

🔬 NAMs Value Drivers

  • Replace 40-60% of preclinical animal studies
  • Reduce late-stage attrition by 10-20%
  • Accelerate go/no-go decisions
  • Enable patient stratification earlier
  • Better human translatability data

📊 Data Sources

  • Tufts CSDD drug development studies
  • BIO Industry Analysis reports
  • FDA clinical trial databases
  • Pharma company financial disclosures
  • Academic cost-effectiveness analyses